"India Pharmaceuticals & Healthcare Report Q2 2013" Is Now Available at Fast Market Research
We maintain our view that growth potential in the Indian pharmaceutical market is reserved for domestic firms, whose lower-priced generic product portfolios align with the government's aim to lower out-of-pocket healthcare expenditure through lower drug prices. Uncertainties in pharmaceutical regulation, especially in the areas of intellectual property protection, will mean multinationals will remain hesitant to enter this market. For these reasons, we continue to see domestic firms outperforming in India.
View full press release